Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.

Urbina O, Ferrández O, Espona M, Salas E, Ferrández I, Grau S.

Drug Des Devel Ther. 2013 Apr 3;7:243-65. doi: 10.2147/DDDT.S30728. Review.

2.

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Review.

PMID:
25673021
3.

Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.

McBride D, Krekel T, Hsueh K, Durkin MJ.

Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):331-337. doi: 10.1080/17425255.2017.1290080. Review.

PMID:
28140693
4.

Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections.

Chahine EB, Sucher AJ, Knutsen SD.

Consult Pharm. 2015 Jul;30(7):386-94. doi: 10.4140/TCP.n.2015.386. Review.

PMID:
26173190
5.

Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.

Burdette SD, Trotman R.

Clin Infect Dis. 2015 Oct 15;61(8):1315-21. doi: 10.1093/cid/civ501. Review.

PMID:
26105167
6.

Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.

Rybak JM, Marx K, Martin CA.

Pharmacotherapy. 2014 Nov;34(11):1198-208. doi: 10.1002/phar.1491. Review.

PMID:
25266820
7.

Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.

Ortiz-Covarrubias A, Fang E, Prokocimer PG, Flanagan SD, Zhu X, Cabré-Márquez JF, Tanaka T, Passarell J, Fiedler-Kelly J, Nannini EC.

Braz J Infect Dis. 2016 Mar-Apr;20(2):184-92. doi: 10.1016/j.bjid.2015.12.007.

8.

In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China.

Li S, Guo Y, Zhao C, Chen H, Hu B, Chu Y, Zhang Z, Hu Y, Liu Z, Du Y, Gui Q, Ji P, Zeng J, Cao B, Fu Q, Zhang R, Wang Z, Zhuo C, Feng X, Jia W, Jin Y, Xu X, Liao K, Ni Y, Yu Y, Xu X, Hu Z, Lei JE, Yang Q, Wang H.

J Med Microbiol. 2016 Oct;65(10):1215-1224. doi: 10.1099/jmm.0.000347.

PMID:
27599998
10.

Tedizolid for treatment of acute bacterial skin and skin structure infections.

Hui Y, Xiaoju L.

Expert Rev Anti Infect Ther. 2015;13(9):1051-60. doi: 10.1586/14787210.2015.1073107. Review.

PMID:
26211946
11.

In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.

Chen KH, Huang YT, Liao CH, Sheng WH, Hsueh PR.

Antimicrob Agents Chemother. 2015 Oct;59(10):6262-5. doi: 10.1128/AAC.00390-15.

12.
13.

Tedizolid: a new oxazolidinone antimicrobial.

Kisgen JJ, Mansour H, Unger NR, Childs LM.

Am J Health Syst Pharm. 2014 Apr 15;71(8):621-33. doi: 10.2146/ajhp130482. Review.

PMID:
24688035
14.

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P.

Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6.

PMID:
24909499
15.

Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.

Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G.

Ann Clin Microbiol Antimicrob. 2014 Sep 20;13:46. doi: 10.1186/s12941-014-0046-0.

16.

Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.

Douros A, Grabowski K, Stahlmann R.

Expert Opin Drug Metab Toxicol. 2015;11(12):1849-59. doi: 10.1517/17425255.2015.1098617. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2015;11(12):v.

PMID:
26457865
17.

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Prokocimer P, De Anda C, Fang E, Mehra P, Das A.

JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241.

PMID:
23403680
18.

Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.

Barber KE, Smith JR, Raut A, Rybak MJ.

J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302.

PMID:
26476277
19.

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.

Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR.

Antimicrob Agents Chemother. 2012 Nov;56(11):5916-22. doi: 10.1128/AAC.01303-12.

20.

In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P.

Antimicrob Agents Chemother. 2013 Jul;57(7):3060-6. doi: 10.1128/AAC.00431-13.

Supplemental Content

Support Center